IRIS
RENDA, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.341
AS - Asia 5.249
EU - Europa 4.373
SA - Sud America 885
Continente sconosciuto - Info sul continente non disponibili 688
AF - Africa 76
OC - Oceania 4
Totale 19.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.144
SG - Singapore 2.237
CN - Cina 1.294
IT - Italia 737
BR - Brasile 726
IE - Irlanda 690
UA - Ucraina 641
RU - Federazione Russa 598
VN - Vietnam 545
TR - Turchia 502
SE - Svezia 494
GB - Regno Unito 327
DE - Germania 283
FR - Francia 212
FI - Finlandia 160
BD - Bangladesh 133
IN - India 123
HK - Hong Kong 101
CA - Canada 88
AR - Argentina 66
MX - Messico 61
PL - Polonia 51
IQ - Iraq 43
ID - Indonesia 40
JP - Giappone 37
NL - Olanda 32
AT - Austria 30
EC - Ecuador 28
ZA - Sudafrica 28
IR - Iran 27
ES - Italia 24
BE - Belgio 23
PK - Pakistan 20
CO - Colombia 18
KR - Corea 18
VE - Venezuela 17
EG - Egitto 16
PH - Filippine 16
LT - Lituania 15
CR - Costa Rica 13
JO - Giordania 13
UZ - Uzbekistan 13
NP - Nepal 11
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
EU - Europa 10
IL - Israele 10
JM - Giamaica 10
MY - Malesia 10
CL - Cile 9
CZ - Repubblica Ceca 9
SA - Arabia Saudita 8
RO - Romania 7
HN - Honduras 6
KE - Kenya 6
KZ - Kazakistan 6
MA - Marocco 6
OM - Oman 6
CH - Svizzera 5
HU - Ungheria 5
TN - Tunisia 5
UY - Uruguay 5
DK - Danimarca 4
DZ - Algeria 4
TT - Trinidad e Tobago 4
AU - Australia 3
BH - Bahrain 3
GR - Grecia 3
GT - Guatemala 3
LB - Libano 3
SN - Senegal 3
SV - El Salvador 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BO - Bolivia 2
EE - Estonia 2
GD - Grenada 2
GE - Georgia 2
LV - Lettonia 2
MD - Moldavia 2
MK - Macedonia 2
NE - Niger 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BJ - Benin 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
Totale 18.919
Salva come PNG Salva come JPEG
Città #
Singapore 1.598
Dallas 872
San Jose 820
Jacksonville 757
Dublin 671
Chandler 649
Ashburn 532
Council Bluffs 470
Princeton 337
Beijing 297
Izmir 224
Los Angeles 214
Ho Chi Minh City 202
Nanjing 201
Southend 196
Santa Clara 169
New York 139
Hanoi 129
Altamura 118
Dearborn 117
Cambridge 116
Wilmington 113
Tongling 107
The Dalles 104
Hong Kong 98
Nanchang 87
Ann Arbor 79
Buffalo 77
Chieti 71
São Paulo 66
Moscow 64
Redondo Beach 59
Munich 56
Phoenix 54
Columbus 44
Pescara 43
Boardman 41
Hebei 39
Orem 39
Shenyang 39
Woodbridge 39
Chicago 36
Kunming 35
Tokyo 35
Hefei 34
Montreal 33
Brooklyn 31
Warsaw 30
Tianjin 29
Atlanta 28
Augusta 28
Denver 28
Milan 27
San Francisco 27
Houston 26
Haiphong 25
Washington 25
Changsha 24
Da Nang 24
Rio de Janeiro 24
Rome 24
Stockholm 24
Jiaxing 23
San Mateo 23
Brussels 22
Grevenbroich 22
Johannesburg 22
London 22
Mexico City 22
Norwalk 22
Lappeenranta 21
Toronto 21
Leawood 20
Helsinki 19
Brasília 18
Seattle 18
Amsterdam 17
Ardabil 17
Camerino 17
Frankfurt am Main 17
Nuremberg 17
Teramo 17
Ankara 16
Baghdad 16
Boston 16
Hangzhou 16
Chennai 15
Dong Ket 15
Falls Church 15
Hải Dương 15
Kraków 15
Poplar 15
Belo Horizonte 14
Guangzhou 14
Mumbai 14
Bologna 13
Tashkent 13
Amman 12
Düsseldorf 12
Porto Alegre 12
Totale 11.399
Salva come PNG Salva come JPEG
Nome #
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 371
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 352
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 290
Increased left atrial size in obese children and its association with insulin resistance: a pilot study 183
Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis 180
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial 174
Effects of endurance, resistance and neuro-muscular electrical stimulation trainings to the anthropometric and functional mobility domains in elderly 174
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 172
La gestione del rischio tromboembolico nei pazienti con fibrillazione atriale in Italia: Dati al follow-up del Registro Europeo PREFER in AF 158
Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents 155
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects 152
Genetic determinants of blood pressure responses to caffeine drinking 152
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy 152
The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy 152
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 152
Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers 148
Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19 143
Echocardiographic screening for the anomalous aortic origin of coronary arteries 143
Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation 141
Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review 141
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery 138
Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions 137
Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial 132
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 132
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors 131
Aneurisma coronarico: scoperta generalmente casuale, prognosi sempre severa? 128
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry 128
Ex Vivo Antiplatelet Effects of Oral Anticoagulants 126
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 126
Risk of Atrial Fibrillation in Masked and White Coat Uncontrolled Hypertension 126
Facilitated PCI: Rationale, current evidence, open questions and future directions 125
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 125
Edoxaban for the Prevention of Thromboembolism in Patients with Atrial Fibrillation and Bioprosthetic Valves 124
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions 124
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 124
Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis 124
Coffee: Health Effects 123
Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin 123
Prognostic value of non-resistant and resistant masked uncontrolled hypertension detected by ambulatory blood pressure monitoring 123
Ambulatory blood pressure and risk of new-onset atrial fibrillation in treated hypertensive patients 122
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 121
Cardiovascular and psychological reactivity after caffeine consumption 121
Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies 121
Prevention of cardiotoxicity in childhood cancer survivors: in physical exercise, we trust 120
EFFECTS OF NIMESULIDE ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN MAN. 120
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 119
Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry 119
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease 119
Predictive Value of Left Atrial and Ventricular Strain for the Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke 118
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 118
The left atrial appendage: from embryology to prevention of thromboembolism 118
Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study 118
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 118
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 117
The legacy of ISCHEMIA 117
The AVERROES Trial – Clinical Implications 116
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries 116
Autonomic nervous system dysfunction in obese children 115
An early decline of collateral circulation parallels myocardial ischaemia during percutaneous coronary intervention: a drawback of recanalization of chronic coronary occlusions? 115
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation 115
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy 114
Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation ∗ 114
Blood pressure modifications after caffeine intake during cognitive tasks 113
Cardiovascular effects of caffeine during cognitive tasks 113
Non-vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation - An Updated Meta-analysis 113
Prognostic Significance of Chest Imaging by LUS and CT in COVID-19 Inpatients: The ECOVID Multicenter Study 113
Predictors of Mortality and Cardiovascular Outcome at 6 Months after Hospitalization for COVID-19 113
Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives 112
Antithrombotic therapy in atrial fibrillation: state of the art and perspectives. 112
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF 112
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 111
Systolic and diastolic dysfunction occurs in newly diagnosed patients with hypertension and high systolic blood pressure variability 111
Ruolo del fibrinogeno e della conta piastrinica sull’inibizione dell’aggregazione piastrinica da parte dei farmaci anti-glicoproteina IIbIIIa 110
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 110
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial 110
CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation 109
INCREASED THROMBOXANE PRODUCTION BY MONOCYTE PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. 108
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. 108
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 108
New anticoagulants for atrial fibrillation 107
Preeclampsia: Insights into pathophysiological mechanisms and preventive strategies 106
Nutrigenetics of blood pressure responses to coffee drinking 106
Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban 105
Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies 105
Systolic blood pressure variability by non-invasive monitoring predicts intima-media thickness independent of absolute blood pressure levels 104
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper 104
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 103
Atrial and left atrial appendage thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 103
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 102
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W 102
Measurements of thromboxane production and their clinical significance in coronary heart disease 102
Prognostic significance of noncardiac syncope in the general population: A systematic review and meta-analysis 102
AF: current and forthcoming antithrombotic therapies 102
Case Report: Mitral Valve Involvement and First-Degree Atrial-Ventricular Block in Two Patients With Multisystem Inflammatory Syndrome in Children 101
Tracing Visual Expertise in ECG Interpretation: An Eye‐Tracking Pilot Study 100
MECHANISMS OF ISOPROSTANE BIOSYNTHESIS IN HUMANS 100
A comparison between unfractionated heparin and a low molecular weight heparin in cardiac surgery 100
PrevenTion of contrast-inducEd nephropAThy with urinE alkalinization: the TEATE study design 100
Surgical bleeding after preoperative unfractionated heparin and low molecular weight heparin at coronary bypass surgery 99
Circadianicity of hemostatic function and coronary vasomotion 98
Totale 12.852
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.112
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022674 0 0 5 126 82 8 17 62 64 18 71 221
2022/20232.004 182 282 117 193 181 391 139 137 268 23 51 40
2023/2024961 75 17 57 11 51 299 221 46 11 29 30 114
2024/20252.732 168 442 348 83 61 96 88 124 314 192 303 513
2025/20267.423 485 291 1.271 995 624 390 977 422 739 562 516 151
2026/20271.297 286 543 468 0 0 0 0 0 0 0 0 0
Totale 19.616